The U.S. Army Medical Research and Development Command (USAMRDC) selected the Army Liposome Formulation with QS21 (ALFQ) as one of the 2020 award recipients. ALFQ was developed by MHRP at Walter Reed Army Institute of Research (WRAIR) scientists and was awarded a patent in 2019. This Army-owned and developed adjuvant, ALFQ, has shown to be strongly potent as a vaccine adjuvant in preclinical studies.
A recent study that sought to characterize the structure and genetic features of HIV-1 antibodies from vaccinated rhesus macaques isolated four identical neutralizing antibody (nAb) lineages across multiple animals.
MHRP last week launched a Phase 2 clinical trial in Thailand to evaluate an interleukin-15 (IL-15) superagonist, ImmunityBio’s Anktiva®, administered during acute HIV infection as an experimental therapy to target establishment of the HIV reservoir at a very early stage.
